About Novocure
Novocure is a publicly listed company based in Haifa (Israel) founded in 2000. Therapeutics for solid tumors are developed via Tumor Treating Fields. It operates on a HealthTech model. Novocure has raised $10 million across 3 funding rounds from investors including Pfizer Venture Investments, Johnson & Johnson Innovation – JJDC and Index Ventures. The company has 1,490 employees. Its website novocure.com draws about 38 thousand monthly visits. Novocure offers products and services including Optune Gio and Optune Lua. Its focus areas include Medical Devices and Oncology Devices. Its legal entity is Novocure GmbH.
Company details
Novocure is a global oncology company dedicated to extending survival in patients with some of the most aggressive forms of cancer. The company specializes in Tumor Treating Fields (TTFields) therapy, a novel approach to cancer treatment. Products like Optune Gio and Optune Lua are developed to target specific cancer types. Research and clinical trials, such as the PANOVA-3 trial for pancreatic cancer, are conducted to advance therapeutic solutions. Operations span multiple regions including North America, Europe, and Asia. Collaboration with patients and healthcare professionals is emphasized to improve outcomes in oncology.
- Headquarters Haifa, Israel
- Employees 1,490
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website novocure.com
- Social LinkedIn X
- Legal Name Novocure Limited
- Annual Revenue$655.35 M (USD)8.28as on Dec 31, 2025
- Net Profit-$136.23 M (USD)19.21as on Dec 31, 2025
- EBITDA-$137.44 M (USD)12.07as on Dec 31, 2025
- Total Equity Funding$10M (USD)
in 3 rounds
- Latest Funding Round$500M (USD), Post-IPO
Nov 2020
- InvestorsPfizer Venture Investments
& 2 more
- Employee Count1,490
Products & Services of Novocure
Novocure offers a comprehensive portfolio of products and services, including Optune Gio and Optune Lua.
A device for treating aggressive cancer with TTFields.
A therapy device using TTFields for cancer treatment.
Funding Insights of Novocure
Novocure has successfully raised a total of $10M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $500 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10M
- Total Rounds 3
- Last Round Post-IPO — $500M
- Investors Count 3
All 3 funding rounds of Novocure with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2020 | $500M | Post-IPO | – | – | – |
| Jun 2010 | $10M | Series A | – | Pfizer Venture Investments, Johnson & Johnson Innovation – JJDC | – |
| Sep 2009 | Series A | – | Johnson & Johnson Innovation – JJDC, Pfizer Venture Investments |
3 investors in total: 3 institutional.
Investors in Novocure
Novocure has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Pfizer Venture Investments, Johnson & Johnson Innovation – JJDC and Index Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is focused on healthcare by Pfizer's investment arm. | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | ||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Venture capital investments in technology startups and entrepreneurs. | indexventures.com |
Investor details for Novocure
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Novocure
287 people are tracked at Novocure (87 in leadership, 10 in board & advisors, 190 in team); the tracked headcount is 1,490.
| Name | Role | Group |
|---|---|---|
Frank Leonard | President, CNS Cancers U.S. | Leadership |
Nicole Dimartino | Associate Director | Leadership |
Randy Miller | National Director Of Sales - US CNS Franchise | Leadership |
Hans Hubregtse | Vice President Corporate Finance | Leadership |
Ingrid Goldberg | Vice President, Finance And Investor Relations | Leadership |
Logan Anderson | Director, Brand Counsel | Leadership |
Uri Weinberg | Chief Innovation Officer | Leadership |
Dave Blazina | Vice President, Lead Brand Counsel | Leadership |
Madeline Wirth | Global Head Of Learning & Development | Leadership |
Galit Katz | Senior Talent Acquisition Partner | Leadership |
Asaf Danziger | CEO | Leadership |
Moshe Giladi | Chief Science Officer | Leadership |
Marta Coloszynska | Director, Head Of Compliance EMEA | Leadership |
Wilco Groenhuysen | COO | Leadership |
Ashley Cordova | CFO | Leadership |
Mauro Bättig | Head Of Accounting EMEA | Leadership |
Vincent Keefe | Vice President Marketing | Leadership |
Eyal Dor-On | Director Of Early Translation | Leadership |
Trey Jacobson | Director, EMEA New Markets And Global Accounts Receivable | Leadership |
Eyal Wolf | Director, Finance | Leadership |
267 more people are available in the full profile.
Complete people profiles for Novocure
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Novocure
Novocure is a publicly listed company on the NASDAQ with ticker symbol NVCR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 Oct 2015
- Listed onNASDAQ: NVCR
- Listed entityNovoCure Limited
- Exchange sectorHealth technology
- ISINJE00BYSS4X48
- Share price$14.30 (-2.85% on the day) · 2026-10-13
- Market capitalisation$1.67B
- EPS (diluted, trailing year)$-1.31
- Volume (last session)772,628
Financials of Novocure
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $655.4M | -$136.2M | -$137.4M |
| 2024 | $605.2M | -$168.6M | -$156.3M |
| 2023 | $509.3M | -$207.0M | -$215.2M |
| 2022 | $537.8M | -$92.5M | -$78.3M |
| 2021 | $535.0M | -$58.4M | -$33.4M |
Detailed financial statements for Novocure
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Novocure
4 dated milestones of Novocure across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Novocure is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $500.0M.
Web traffic of Novocure
The website of Novocure (novocure.com) receives about 37.8K visits a month and ranks #872,540 among all websites worldwide, #1,054 in Biotechnology and Pharmaceuticals.
- Monthly visits37.8K
▲ 13.3% vs previous month
- Unique visitors15.5K
per month
- Global rank#872,540
among all websites
- Category rank#1,054
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit2.0
- Average visit1 min 06 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Novocure. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biodesix.com | 100% | 7.4K | #2,413,737 | View details | |
| agennix.com | 97% | View details | |||
| sekisuidiagnostics.com | 68% | #2,255,959 | View details | ||
| discoverymedicine.com | 61% | #1,970,320 | View details | ||
| hologic.com | 58% | 185.1K | #258,622 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Novocure
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novocure
Complete news archive for Novocure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novocure
Novocure was founded in 2000 and raised its 1st funding round 9 years after it was founded.
Novocure is headquartered in Haifa, Israel. It is registered at Haifa, Haifa District, Israel.
Novocure is a funded company, having raised a total of $10M across 3 funding rounds to date.
Novocure has 1,490 employees.
Annual revenue of Novocure is $655.35M as on Dec 31, 2025.
Novocure is a global oncology company dedicated to extending survival in patients with some of the most aggressive forms of cancer. The company specializes in Tumor Treating Fields (TTFields) therapy, a novel approach to cancer treatment. Products like Optune Gio and Optune Lua are developed to target specific cancer types. Research and clinical trials, such as the PANOVA-3 trial for pancreatic cancer, are conducted to advance therapeutic solutions. Operations span multiple regions including North America, Europe, and Asia. Collaboration with patients and healthcare professionals is emphasized to improve outcomes in oncology.
Novocure offers Optune Gio and Optune Lua.
Yes, Novocure is publicly traded on NASDAQ under the ticker symbol NVCR.
Novocure has 3 investors. Key investors include Pfizer Venture Investments, Johnson & Johnson Innovation – JJDC, and Index Ventures.
Novocure operates through Novocure Gmbh.